Pharmacological and genetic strategies for targeting adenosine to enhance adoptive T cell therapy of cancer.
Journal
Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
18
05
2020
accepted:
06
07
2020
pubmed:
28
8
2020
medline:
12
10
2021
entrez:
28
8
2020
Statut:
ppublish
Résumé
Adoptive cellular therapy involves the ex vivo expansion of immune cells, conventionally T cells, before reinfusion back to the patient. Variations in adoptive cellular therapy include transduction of a patient's T cells with either a transgenic T cell receptor or chimeric antigen receptor (CAR) to recognize a defined tumor antigen. Given that adenosine is a major axis of immunosuppression of T cells, particularly in hypoxic tumor microenvironments, therapeutics targeting this pathway are currently being assessed for their potential to enhance adoptive T cell therapies. The use of gene-editing technology, commonly used in tandem with CAR and transgenic T cell receptor (TCR) based adoptive cellular therapy, offers further opportunities to specifically modulate responses to adenosine. This review will discuss recent advances in targeting the adenosine pathway for enhancing the effectiveness of adoptive cellular therapy in the treatment of solid cancers.
Identifiants
pubmed: 32854024
pii: S1471-4892(20)30040-0
doi: 10.1016/j.coph.2020.07.002
pii:
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Adenosine
K72T3FS567
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-97Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.